Sherbrooke Park Advisers LLC Buys Shares of 14,865 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Sherbrooke Park Advisers LLC bought a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 14,865 shares of the company’s stock, valued at approximately $188,000.

Other large investors also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth about $31,000. Tower Research Capital LLC TRC lifted its position in shares of Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after purchasing an additional 9,603 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth about $143,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth about $150,000. Finally, Man Group plc acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth about $162,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DAWN shares. JPMorgan Chase & Co. reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Finally, Needham & Company LLC cut their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of “Buy” and an average target price of $30.57.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,552 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $28,495.52. Following the transaction, the general counsel now directly owns 47,136 shares in the company, valued at $295,071.36. This represents a 8.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 13,964 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the transaction, the chief executive officer now owns 145,737 shares in the company, valued at $912,313.62. This represents a 8.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,725 shares of company stock valued at $167,299 over the last 90 days. 6.20% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Stock Up 1.5%

Shares of NASDAQ:DAWN opened at $6.58 on Wednesday. The firm’s 50 day moving average price is $7.36 and its 200 day moving average price is $10.68. The stock has a market cap of $666.96 million, a price-to-earnings ratio of -6.39 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $6.08 and a fifty-two week high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analyst estimates of $30.28 million. On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.